Role of protein kinases in the development of tamoxifen and palbociclib resistance in breast cancer.

NOVARO V; MARKS MP; PERRONE MC; ALCOBER BOQUET L; ENRICO D; POLO ML; VELLÓN L; RIGGIO M; RODRIGUEZ MJ

Congreso; Reunión Conjunta de Sociedades de Biociencias. Noviembre de 2017. Buenos Aires, Argentina; 2017

Sociedades de Biociencias

It is estimated that approximately 70% of breast tumors express hormone receptors for estrogen (ER) and progesterone (PR). Although ER antagonist tamoxifen has been successful for ER+ breast cancer treatment, a signi cant amount of these tumors eventually develop resistance. In order to study this phenomenon, we generated a tamoxifen-resistant cell line derived from the human breast cancer cell line T47D (T47D-TR), by long-term cell exposure to progressively increasing concentrations of tamoxifen. This resis- tant cell line showed an increase in basal activation of ER despite re- duction in its expression levels (p